Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PROCEPT BioRobotics Corporation - Common Stock (NQ:PRCT)

39.46 +0.08 (+0.20%)
Streaming Delayed Price Updated: 12:28 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PROCEPT BioRobotics Corporation - Common Stock

< Previous 1 2 3 Next >
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
From PROCEPT BioRobotics
Via GlobeNewswire
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
From PROCEPT BioRobotics
Via GlobeNewswire
Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
From PROCEPT BioRobotics
Via GlobeNewswire
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a... 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes 
From PROCEPT BioRobotics
Via GlobeNewswire
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?
Surgical robotics company PROCEPT BioRobotics Co. (NASDAQ: PRCT) developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia 
Via MarketBeat
Why Intuitive Surgical Stock is Dominating the Medical Sector
Robotic surgery conjures up futuristic images of automated machines performing surgery on anesthetized human patients in an assembly line. However 
Via MarketBeat
PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
From PROCEPT BioRobotics
Via GlobeNewswire
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH... 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.